EP1710246A1 — Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
Assigned to Bayer Pharma AG · Expires 2006-10-11 · 20y expired
What this patent protects
The invention relates to macrocyclic sulfoximines according to the general Formula I: wherein A, X, Y, R 1 , R 2 and R 3 have the meaning as given in the specification and the claims and the salts thereof; to pharmaceutical compositions comprising the macrocyclic sulfoxim…
USPTO Abstract
The invention relates to macrocyclic sulfoximines according to the general Formula I: wherein A, X, Y, R 1 , R 2 and R 3 have the meaning as given in the specification and the claims and the salts thereof; to pharmaceutical compositions comprising the macrocyclic sulfoximines and to a method of preparing the macrocyclic sulfoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.